Tirzepatide
Also known as: LY3298176
Tirzepatide is a novel dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is designed to mimic the body's natural hormones to regulate blood glucose and influence appetite control.
Molecular Properties
Molecular Formula
C225H348N48O68
Molecular Weight
4813.45
CAS Number
2023788-19-2
Research History
Developed by Eli Lilly and Company, Tirzepatide entered clinical trials as a breakthrough treatment for Type 2 diabetes and metabolic dysfunction. It represents the next generation of multi-receptor agonists, showing superior efficacy in weight management compared to selective GLP-1 analogs.
Studied Mechanisms
Tirzepatide functions by activating both GIP and GLP-1 receptors, which work synergistically to enhance insulin secretion and reduce glucagon levels. It also modulates gastric emptying and promotes satiety via the hypothalamus, making it a focus for chronic weight management studies.
Storage Reference
Store in refrigerator at 2-8°C. Do not freeze.
Handling Reference
Handle with appropriate PPE. Ensure correct dilution protocols.